• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

利福平在治疗复杂肺部疾病中没有作用，需要使用杀菌药物：一个观点。

Rifampicin has no role in treatment of complex pulmonary disease and bactericidal sterilising drugs are needed: a viewpoint.

机构信息

Department of Medical Microbiology, Radboud University Medical Center, Nijmegen, The Netherlands

Department of Pulmonary Diseases, Radboud University Medical Center, Nijmegen, The Netherlands.

出版信息

Eur Respir J. 2024 May 2;63(5). doi: 10.1183/13993003.02210-2023. Print 2024 May.

DOI:10.1183/13993003.02210-2023
PMID:38697635
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11063616/
Abstract

https://bit.ly/3PUGvbV

摘要

[文献链接]

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fbf4/11063616/7232fe7f982a/ERJ-02210-2023.01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fbf4/11063616/7232fe7f982a/ERJ-02210-2023.01.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fbf4/11063616/7232fe7f982a/ERJ-02210-2023.01.jpg

相似文献

1
Rifampicin has no role in treatment of complex pulmonary disease and bactericidal sterilising drugs are needed: a viewpoint.利福平在治疗复杂肺部疾病中没有作用，需要使用杀菌药物：一个观点。
Eur Respir J. 2024 May 2;63(5). doi: 10.1183/13993003.02210-2023. Print 2024 May.
2
Is Dose Adjustment of Prednisolone Required in Patients With IgA Nephropathy During Rifampicin Treatment for Mycobacterium avium Complex Lung Disease?患有鸟分枝杆菌复合群肺病的IgA肾病患者在利福平治疗期间是否需要调整泼尼松龙剂量？
Ther Drug Monit. 2019 Aug;41(4):546-547. doi: 10.1097/FTD.0000000000000647.
3
Relationship between Resistance to Ethambutol and Rifampin and Clinical Outcomes in Mycobacterium avium Complex Pulmonary Disease.分枝杆菌复合群肺病中乙胺丁醇和利福平耐药与临床结局的关系。
Antimicrob Agents Chemother. 2022 Apr 19;66(4):e0202721. doi: 10.1128/aac.02027-21. Epub 2022 Mar 10.
4
Relationship between clinical efficacy of treatment of pulmonary Mycobacterium avium complex disease and drug-sensitivity testing of Mycobacterium avium complex isolates.鸟分枝杆菌复合群肺病治疗的临床疗效与鸟分枝杆菌复合群分离株药敏试验之间的关系
J Infect Chemother. 2006 Aug;12(4):195-202. doi: 10.1007/s10156-006-0457-8.
5
Mycobacterium Growth Indicator Tube Time-To-Positivity Can Serve As an Early Biomarker of Treatment Response in Mycobacterium avium Complex Pulmonary Disease.鸟分枝杆菌复合群肺病中分枝杆菌生长指示管阳性时间可作为治疗反应的早期生物标志物。
Chest. 2022 Feb;161(2):370-372. doi: 10.1016/j.chest.2021.08.046. Epub 2021 Aug 13.
6
Intermittent versus Daily Therapy for Noncavitary Complex Pulmonary Disease: An Open-Label Randomized Trial.非空洞性复杂性肺部疾病的间歇性与每日治疗：一项开放标签随机试验
Ann Am Thorac Soc. 2025 Aug;22(8):1183-1192. doi: 10.1513/AnnalsATS.202406-626OC.
7
Treatment of pulmonary disease caused by Mycobacterium avium complex.鸟分枝杆菌复合体引起的肺部疾病的治疗。
Intern Med. 2003 Aug;42(8):627-8. doi: 10.2169/internalmedicine.42.627.
8
Role of ethambutol and rifampicin in the treatment of Mycobacterium avium complex pulmonary disease.乙胺丁醇和利福平在治疗鸟分枝杆菌复合体肺病中的作用。
BMC Pulm Med. 2019 Nov 11;19(1):212. doi: 10.1186/s12890-019-0982-8.
9
The clinical efficacy of a clarithromycin-based regimen for Mycobacterium avium complex disease: A nationwide post-marketing study.基于克拉霉素的方案治疗鸟分枝杆菌复合群疾病的临床疗效：一项全国性上市后研究。
J Infect Chemother. 2017 May;23(5):293-300. doi: 10.1016/j.jiac.2017.01.007. Epub 2017 Feb 27.
10
The second recurrence of complex lung disease after successful treatment for first recurrence.首次复发成功治疗后复杂性肺部疾病的第二次复发。
Eur Respir J. 2019 Jan 3;53(1). doi: 10.1183/13993003.01038-2018. Print 2019 Jan.

引用本文的文献

1
Current and emerging treatment strategies for complex pulmonary disease: a narrative review.复杂肺部疾病的当前及新出现的治疗策略：一篇叙述性综述
Ewha Med J. 2025 Apr;48(2):e25. doi: 10.12771/emj.2025.00080. Epub 2025 Mar 26.
2
Treatment Outcomes of Complex Pulmonary Disease with a 2-drug Daily Regimen Using Macrolide and Ethambutol.使用大环内酯类药物和乙胺丁醇每日两药方案治疗复杂肺部疾病的疗效
Open Forum Infect Dis. 2025 May 13;12(6):ofaf292. doi: 10.1093/ofid/ofaf292. eCollection 2025 Jun.
3
Detection of a Mixed-Strain Infection with Drug- and Multidrug-Resistant Subspecies in a Dog with Generalized Lymphadenomegaly.

本文引用的文献

1
Safety and Efficacy of Clofazimine as an Alternative for Rifampicin in Mycobacterium avium Complex Pulmonary Disease Treatment: Outcomes of a Randomized Trial.氯法齐明作为替代利福平治疗鸟分枝杆菌复合体肺病的安全性和疗效：一项随机试验的结果。
Chest. 2024 May;165(5):1082-1092. doi: 10.1016/j.chest.2023.11.038. Epub 2023 Nov 29.
2
The role of rifampicin within the treatment of pulmonary disease.利福平在肺部疾病治疗中的作用。
Antimicrob Agents Chemother. 2023 Nov 15;67(11):e0087423. doi: 10.1128/aac.00874-23. Epub 2023 Oct 25.
3
Towards clinical breakpoints for non-tuberculous mycobacteria - Determination of epidemiological cut off values for the Mycobacterium avium complex and Mycobacterium abscessus using broth microdilution.
一只患有全身性淋巴结肿大的犬体内药物及多重耐药亚种混合菌株感染的检测
Antibiotics (Basel). 2025 Apr 19;14(4):416. doi: 10.3390/antibiotics14040416.
4
Effect of Individual Agents on Time to Culture Conversion in Complex Pulmonary Disease.个体药物对复杂肺部疾病培养转化时间的影响。
Open Forum Infect Dis. 2025 Mar 7;12(3):ofaf138. doi: 10.1093/ofid/ofaf138. eCollection 2025 Mar.
5
A Year in Review on Tuberculosis and Non-tuberculous Mycobacteria Disease: A 2025 Update for Clinicians and Scientists.结核病和非结核分枝杆菌病年度回顾：2025年临床医生和科学家最新进展
Pathog Immun. 2025 Mar 2;10(2):1-45. doi: 10.20411/pai.v10i2.791. eCollection 2025.
6
Tolerability and efficacy of Mycobacterium avium complex pulmonary disease treatment in elderly patients.老年鸟分枝杆菌复合群肺病治疗的耐受性和疗效
BMC Pulm Med. 2025 Feb 7;25(1):67. doi: 10.1186/s12890-025-03504-4.
7
Rational Exploration of 2,4-Diaminopyrimidines as DHFR Inhibitors Active against and , Two Emerging Human Pathogens.理性探索 2,4-二氨基嘧啶作为对 和 的 DHFR 抑制剂，这两种新兴的人类病原体。
J Med Chem. 2024 Nov 14;67(21):19143-19164. doi: 10.1021/acs.jmedchem.4c01594. Epub 2024 Oct 28.
8
Toward better cures for lung disease.寻求更好的肺部疾病治疗方法。
Clin Microbiol Rev. 2024 Dec 10;37(4):e0008023. doi: 10.1128/cmr.00080-23. Epub 2024 Oct 3.
9
Prescription habits and drugs accessibility for the treatment of non-tuberculous mycobacteria infections in Italy: a multicentric survey from the IRENE study group.意大利非结核分枝杆菌感染治疗的处方习惯和药物可及性：IRENE研究组的多中心调查
Infection. 2025 Feb;53(1):383-392. doi: 10.1007/s15010-024-02390-y. Epub 2024 Sep 20.
10
Drug-drug interactions in the management of non-tuberculous mycobacterial infections.非结核分枝杆菌感染管理中的药物相互作用。
Front Microbiol. 2024 Sep 5;15:1468383. doi: 10.3389/fmicb.2024.1468383. eCollection 2024.
迈向非结核分枝杆菌临床折点 - 使用肉汤微量稀释法测定鸟分枝杆菌复合群和脓肿分枝杆菌的流行病学切点值。
Clin Microbiol Infect. 2023 Jun;29(6):758-764. doi: 10.1016/j.cmi.2023.02.007. Epub 2023 Feb 20.
4
Redesign of Rifamycin Antibiotics to Overcome ADP-Ribosylation-Mediated Resistance.重新设计利福霉素抗生素以克服 ADP-核糖基化介导的耐药性。
Angew Chem Int Ed Engl. 2022 Nov 7;61(45):e202211498. doi: 10.1002/anie.202211498. Epub 2022 Oct 12.
5
Relationship between Resistance to Ethambutol and Rifampin and Clinical Outcomes in Mycobacterium avium Complex Pulmonary Disease.分枝杆菌复合群肺病中乙胺丁醇和利福平耐药与临床结局的关系。
Antimicrob Agents Chemother. 2022 Apr 19;66(4):e0202721. doi: 10.1128/aac.02027-21. Epub 2022 Mar 10.
6
Mycobacterium Growth Indicator Tube Time-To-Positivity Can Serve As an Early Biomarker of Treatment Response in Mycobacterium avium Complex Pulmonary Disease.鸟分枝杆菌复合群肺病中分枝杆菌生长指示管阳性时间可作为治疗反应的早期生物标志物。
Chest. 2022 Feb;161(2):370-372. doi: 10.1016/j.chest.2021.08.046. Epub 2021 Aug 13.
7
Comparison of Rifamycins for Efficacy Against Complex and Resistance Emergence in the Hollow Fiber Model System.利福霉素在中空纤维模型系统中对复杂性和耐药性产生的疗效比较
Front Pharmacol. 2021 Apr 15;12:645264. doi: 10.3389/fphar.2021.645264. eCollection 2021.
8
On the Consequences of Poorly Defined Breakpoints for Rifampin Susceptibility Testing of Mycobacterium tuberculosis Complex.结核菌复合群利福平药敏试验中界定不当的断点的后果
J Clin Microbiol. 2021 Mar 19;59(4). doi: 10.1128/JCM.02328-20.
9
Increased bactericidal activity but dose-limiting intolerability at 50 mg·kg rifampicin.利福平 50mg·kg 时杀菌活性增加，但剂量限制不耐受。
Eur Respir J. 2021 Jul 8;58(1). doi: 10.1183/13993003.00955-2020. Print 2021 Jul.
10
Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline.非结核分枝杆菌肺病的治疗：美国胸科学会/欧洲呼吸学会/欧洲临床微生物学与感染病学会/美国感染病学会官方临床实践指南
Eur Respir J. 2020 Jul 7;56(1). doi: 10.1183/13993003.00535-2020. Print 2020 Jul.